BIOLOGIC AGENTS AND IMMUNOTHERAPY IN RHEUMATOID ARTHRITIS
- 1 August 1998
- journal article
- review article
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 24 (3) , 537-565
- https://doi.org/10.1016/s0889-857x(05)70025-9
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Attenuation of collagen‐induced arthritis in mice by treatment with vector cells engineered to secrete interleukin‐13European Journal of Immunology, 1996
- Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2European Journal of Immunology, 1996
- T-cell activation: integration of signals from the antigen receptor and costimulatory moleculesImmunology Today, 1995
- THE THERAPEUTIC EFFECTS OF AN ENGINEERED HUMAN ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY (CDP571) IN RHEUMATOID ARTHRITISRheumatology, 1995
- DAB486IL‐2 fusion toxin in refractory rheumatoid arthritisArthritis & Rheumatism, 1993
- The importance of the t cell in initiating and maintaining the chronic synovitis of rheumatoid arthritisArthritis & Rheumatism, 1992
- Treatment of collagen‐induced arthritis in rats with a monoclonal antibody against the α/β T cell antigen receptorArthritis & Rheumatism, 1991
- Treatment of rheumatoid arthritis with monoclonal CD4 antibody M‐T151. Clinical results and immunopharmacologic effects in an open study, including repeated administrationArthritis & Rheumatism, 1991
- Treatment of rheumatoid arthritis with an anti‐CD4 monoclonal antibodyArthritis & Rheumatism, 1991
- Peptide competition for antigen presentationImmunology Today, 1990